Pharmexa adds two strong new members to board of directors
Advertisement
Karen Lykke Sørensen, General Manager for Sanofi-Aventis in Denmark and Ole Steen Andersen, Executive Vice President and CFO in Danfoss A/S, will - upon being elected at the next general assembly in Pharmexa - join Pharmexa's board of directors.
Karen Lykke Sørensen has more than 12 years experience in the pharma- and biotech industry in France, Scandinavia and Denmark. She has been General Manager for Sanofi-Aventis' Danish subsidiary since the beginning of 2006. From 2001 to 2006 Karen Lykke Sørensen was Vice President, Global Cardiovascular Business Unit. Before Sanofi-Aventis, Karen Lykke Sørensen was Managing Director, Nordic Countries, in Biogen. Before that, she held senior positions in DAKO and Novo Nordisk. Karen Lykke Sørensen holds a degree in Engineering and an MBA from INSEAD.
Ole Steen Andersen has been Executive Vice President since 1994 and Chief Financial Officer since 2000 in Danfoss A/S. In May 2006 he announced his plans to retire in connection with the annual general assembly in Danfoss in 2007. Before Danfoss, from 1986 to 1993, Ole Steen Andersen was President in NKT Holding A/S, where he also, from 1979 to 1986, held a number of senior positions. Ole Steen Andersen is a member of the board of representatives for the Confederation of Danish Industries, a member of the board of representatives for the Confederation of Danish Employers as well as a member of the board of representatives for the Confederation of Danish Employers outside Copenhagen. He is chairman of the board of directors in COWI A/S and vice chairman in Auriga Industries A/S. He is a member of the board of directors in DT Holding 1 (Danske Trælast) and sits on the boards of a number of companies in the Danfoss group. Ole Steen Andersen holds a master degree in Engineering and a graduate diploma in business administration and has studied at Sloan School of Management, MIT.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Antisense Pharma Granted Patents on Medical Device for Application of Neurotherapeutics
Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs
Parkinson’s researchers test a new approach against motor disorders
New virus drug will have to shoot at moving targets
New research may lead to improved diagnosis of autism
BioGaia initiates investigative study in type 2 diabetics
Viruses flourish in guts of healthy babies
Amorfix Life Sciences and Biogen Idec to collaborate on research for ALS disease
